No Data
No Data
Insider Purchase: Chief Commercial Officer of $XFOR Buys 13,404 Shares
X4 Pharmaceuticals Analyst Ratings
Piper Sandler Maintains X4 Pharmaceuticals(XFOR.US) With Buy Rating, Maintains Target Price $2
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), X4 Pharmaceuticals (XFOR) and IQVIA Holdings (IQV)
H.C. Wainwright Maintains X4 Pharmaceuticals(XFOR.US) With Buy Rating, Maintains Target Price $1.5
Strategic Restructuring and Market Opportunities Drive Buy Rating for X4 Pharmaceuticals
Unlock the Full List